These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10160021)

  • 1. Making cost assessments based on RCTs more useful to decision-makers.
    Baltussen R; Ament A; Leidl R
    Health Policy; 1996 Sep; 37(3):163-83. PubMed ID: 10160021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities.
    Hoffmann C; Stoykova BA; Nixon J; Glanville JM; Misso K; Drummond MF
    Value Health; 2002; 5(2):71-8. PubMed ID: 11918822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of economic evaluation in health care: Australian decision makers' perceptions.
    Ross J
    Health Policy; 1995 Feb; 31(2):103-10. PubMed ID: 10141251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of health-related economic evaluations in Australia: implications for health policy.
    Salkeld G; Davey P; Arnolda G
    Health Policy; 1995 Feb; 31(2):111-25. PubMed ID: 10141252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of health care and policymaking.
    Johannesson M
    Health Policy; 1995 Sep; 33(3):179-90. PubMed ID: 10145120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision makers' views on health care objectives and budget constraints: results from a pilot study.
    Al MJ; Feenstra T; Brouwer WB
    Health Policy; 2004 Oct; 70(1):33-48. PubMed ID: 15312708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules.
    O'Brien BJ; Sculpher MJ
    Med Care; 2000 May; 38(5):460-8. PubMed ID: 10800973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
    Blommestein HM; Franken MG; Uyl-de Groot CA
    Pharmacoeconomics; 2015 Jun; 33(6):551-60. PubMed ID: 25644460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dollar is a dollar is a dollar--or is it?
    Brouwer WB; van Exel NJ; Baltussen RM; Rutten FF
    Value Health; 2006; 9(5):341-7. PubMed ID: 16961552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation.
    Stevens W; Normand C
    Soc Sci Med; 2004 Jan; 58(2):315-20. PubMed ID: 14604617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research into the use of health economics in decision making in the United Kingdom--Phase II. Is health economics 'for good or evil'?
    Duthie T; Trueman P; Chancellor J; Diez L
    Health Policy; 1999 Jan; 46(2):143-57. PubMed ID: 10346286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2003 Dec; 57(11):2207-15. PubMed ID: 14512250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of programmes aiming at eradicating infectious diseases.
    Gyldmark M; Alban A
    Health Policy; 1998 Jul; 45(1):69-79. PubMed ID: 10183014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions.
    Grutters JP; Seferina SC; Tjan-Heijnen VC; van Kampen RJ; Goettsch WG; Joore MA
    Value Health; 2011; 14(5):777-84. PubMed ID: 21839418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of cancer treatments: methodological and practical issues.
    Uyl-de Groot CA; Touw CR
    Anticancer Drugs; 1998 Nov; 9(10):835-41. PubMed ID: 9890694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.